HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

C E M Griffiths Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

2/2022Physical activity is important for cardiovascular health and cardiorespiratory fitness in patients with psoriasis.
1/2022Tender facial nodules in a man receiving adalimumab for psoriasis.
12/2021Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.
12/2021Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
12/2021Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
11/2021Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study.
11/2021The promise and challenges of cell therapy for psoriasis.
11/2021The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
11/2021Patient preferences for stratified medicine in psoriasis: a discrete choice experiment.
10/2021Defining trajectories of response in patients with psoriasis treated with biologic therapies.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


C E M Griffiths Research Topics

Disease

127Psoriasis (Pustulosis Palmaris et Plantaris)
02/2022 - 03/2002
18Necrosis
12/2021 - 01/2002
11Psoriatic Arthritis
12/2021 - 03/2005
8Infections
11/2021 - 06/2005
7Inflammation (Inflammations)
04/2020 - 01/2002
6Skin Diseases (Skin Disease)
04/2020 - 10/2002
5Neoplasms (Cancer)
11/2021 - 07/2009
5Atopic Dermatitis (Atopic Eczema)
07/2020 - 08/2002
4Rheumatoid Arthritis
04/2015 - 05/2008
4Autoimmune Diseases (Autoimmune Disease)
04/2013 - 11/2002
3Myocardial Infarction
04/2020 - 04/2011
3Stroke (Strokes)
04/2020 - 04/2011
3Lichen Planus (Lichen Ruber Planus)
03/2012 - 07/2006
3Pyoderma Gangrenosum
07/2007 - 04/2006
2Chronic Disease (Chronic Diseases)
12/2021 - 12/2009
2Pruritus (Itching)
01/2018 - 12/2005
2Crohn Disease (Crohn's Disease)
04/2015 - 08/2007
2Wounds and Injuries (Trauma)
07/2014 - 03/2012
2Dermatitis
07/2007 - 07/2006
2Chronic Urticaria
07/2007 - 07/2006
2Blister (Bulla)
05/2006 - 05/2003
1Ankylosing Spondylitis
11/2021
1Obesity
11/2021
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
08/2021
1COVID-19
01/2021
1Eosinophilia
07/2020
1Eczema
07/2020
1Unstable Angina
04/2020
1Acute Coronary Syndrome
04/2020
1Anxiety Disorders (Anxiety Disorder)
01/2019
1Bipolar Disorder (Manic Depressive Psychosis)
01/2019

Drug/Important Bio-Agent (IBA)

21Biological ProductsIBA
12/2021 - 09/2005
19Etanercept (Enbrel)FDA Link
12/2021 - 10/2002
15Ustekinumab (CNTO 1275)FDA Link
12/2021 - 10/2010
14Adalimumab (Humira)FDA Link
01/2022 - 08/2009
13InterleukinsIBA
12/2021 - 07/2011
10CytokinesIBA
02/2016 - 01/2002
9Infliximab (Remicade)FDA Link
01/2019 - 10/2002
8Methotrexate (Mexate)FDA LinkGeneric
04/2020 - 11/2005
7secukinumabIBA
12/2021 - 04/2017
7Pharmaceutical PreparationsIBA
11/2021 - 04/2002
6Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2019 - 04/2002
6Monoclonal AntibodiesIBA
01/2018 - 05/2002
6Proteins (Proteins, Gene)FDA Link
04/2016 - 10/2002
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2006 - 01/2002
4Immunoglobulin A (IgA)IBA
12/2021 - 01/2018
4guselkumabIBA
12/2021 - 01/2018
4Immunologic Factors (Immunomodulators)IBA
10/2021 - 12/2019
4Prostaglandins AIBA
01/2020 - 01/2015
3Interleukin-17 (Interleukin 17)IBA
12/2021 - 01/2018
3Interleukin-12 (IL 12)IBA
12/2021 - 04/2017
3Immunomodulating AgentsIBA
11/2021 - 04/2015
3ixekizumabIBA
01/2021 - 04/2017
3GoldIBA
01/2021 - 03/2011
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2020 - 01/2012
3AcitretinFDA Link
01/2019 - 02/2006
2apremilastIBA
12/2021 - 01/2021
2Interleukin-23 Subunit p19IBA
11/2021 - 01/2021
2FumaratesIBA
01/2019 - 09/2005
2Biosimilar PharmaceuticalsIBA
03/2018 - 04/2017
2GP2015IBA
03/2018 - 04/2017
2tofacitinibIBA
02/2017 - 01/2015
2Janus Kinase InhibitorsIBA
02/2017 - 01/2015
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
06/2016 - 01/2012
2Sorafenib (BAY 43-9006)FDA Link
06/2016 - 01/2012
2IGF-I-IGFBP-3 complexFDA Link
04/2016 - 03/2011
2HLA-C Antigens (HLA-C)IBA
04/2015 - 01/2005
26-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA
08/2014 - 02/2006
2omega-Chloroacetophenone (Mace)IBA
04/2013 - 04/2011
2AntigensIBA
03/2012 - 11/2002
2Interleukin-2 (IL2)IBA
03/2011 - 07/2003
2Alefacept (Amevive)FDA Link
08/2009 - 01/2005
2DNA (Deoxyribonucleic Acid)IBA
02/2009 - 02/2006
2Interferon-gamma (Interferon, gamma)IBA
08/2007 - 07/2003
2Interleukin-1beta (Interleukin 1 beta)IBA
08/2007 - 10/2005
2LactoferrinIBA
05/2003 - 01/2002
2Ointments (Pastes)IBA
01/2003 - 03/2002
1Indicators and Reagents (Reagents)IBA
02/2022
1Phosphodiesterase 4 InhibitorsIBA
01/2021
1Immunoglobulin E (IgE)IBA
07/2020
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2020
1Complement System Proteins (Complement)IBA
04/2020
1Prostaglandins FIBA
04/2020
1Placenta Growth FactorIBA
04/2020
1Immunoglobulin G (IgG)IBA
01/2020
1risankizumabIBA
01/2019
1Psychotropic Drugs (Psychoactive Drugs)IBA
01/2019

Therapy/Procedure

51Therapeutics
12/2021 - 03/2002
28Biological Therapy
11/2021 - 08/2008
4Retreatment
02/2017 - 12/2009
4Phototherapy (Light Therapy)
09/2006 - 01/2005
3Photochemotherapy (Photodynamic Therapy)
07/2014 - 12/2004
3Lasers (Laser)
07/2009 - 01/2005
2Aftercare (After-Treatment)
08/2021 - 06/2016
2Duration of Therapy
01/2019 - 05/2004
2Drug Tapering
05/2017 - 06/2005
2Gas Lasers
01/2005 - 12/2002
1Cell- and Tissue-Based Therapy (Cell Therapy)
11/2021
1Treatment Delay
11/2021
1Immunomodulation
10/2018